␣-synuclein and cysteine-string protein-␣ (CSP␣) are abundant synaptic vesicle proteins independently linked to neurodegeneration. Dominantly inherited mutations in ␣-synuclein cause Parkinson's disease, but the physiological role of ␣-synuclein remains unknown. Deletion of CSP␣ produces rapidly progressive neurodegeneration in mice, presumably because the cochaperone function of CSP␣ is essential for neuronal survival. Here, we report the surprising finding that transgenic expression of ␣-synuclein abolishes the lethality and neurodegeneration caused by deletion of CSP␣. Conversely, ablation of endogenous synucleins exacerbates these phenotypes. Deletion of CSP␣ inhibits SNARE complex assembly; transgenic ␣-synuclein ameliorates this inhibition. In preventing neurodegeneration in CSP␣-deficient mice, ␣-synuclein does not simply substitute for CSP␣ but acts by a downstream mechanism that requires phospholipid binding by ␣-synuclein. These observations reveal a powerful in vivo activity of ␣-synuclein in protecting nerve terminals against injury and suggest that this activity operates in conjunction with CSP␣ and SNARE proteins on the presynaptic membrane interface.
Introduction
Presynaptic nerve terminals are specialized secretory machines that release neurotransmitters by synaptic vesicle exocytosis in response to an action potential (Katz, 1969) 
C.S., unpublished data).
These data show that synucleins are not essential for nerve terminal function as such but do not exclude a role that becomes important under exceptional circumstances, for example during stress or injury.
In the present study, we demonstrate that transgenic expression of α-synuclein unexpectedly abolishes the lethal phenotype created by deletion of CSPα in mice. Conversely, knockout of endogenous synucleins accelerates the lethality of the CSPα deletion. We show that CSPα deficiency produces widespread age-dependent neurodegeneration that results in impaired motor performance; these phenotypes are also reversed by transgenic α-synuclein. Transgenic α-synuclein was only active when capable of binding to phospholipid membranes. We also show that one functional effect of the CSPα deletion is a loss of proper SNARE complex assembly, and that this defect is partially corrected by transgenic α-synuclein expression. These observations reveal an in vivo activity of α-synuclein that is powerful enough to abrogate the lethal effects of the CSPα deletion, indicative of a physiological role for α-synuclein in protecting nerve terminals against injury.
Results

Late-Onset Neurodegeneration in Transgenic Mice for Human but Not Mouse ␣-Synuclein
We generated transgenic mice that overexpress wildtype human α-synuclein (htg), A30P mutant human α-synuclein (hA30Ptg), A53T mutant human α-synuclein (hA53Ttg), or wild-type mouse α-synuclein (mtg) under control of the murine Thy-1 promoter. The transgenic mice produced identical levels of α-synuclein overexpression except for the A53T-transgenic mice which exhibited w2-fold higher α-synuclein levels ( Figure 1A ). Immunocytochemistry showed that the various transgenic α-synucleins were expressed in similar panneuronal patterns throughout the brain (see Figure S1 in the Supplemental Data available with this article online).
Consistent with previous reports (reviewed in Fernagut and Chesselet [2004] ), we observed a partially penetrant, age-dependent neurodegenerative disorder in transgenic mice that express wild-type or mutant human α-synucleins. Mice expressing wild-type human α-synuclein exhibited only a modest neurodegenerative phenotype (w15% incidence after 16 months). However, mice containing transgenic A30P-or A53T mutant human α-synuclein displayed a more severe phenotype (>70% incidence; Figure 1B ). This result confirms previous studies demonstrating that in transgenic mice, α-synuclein with a Parkinson's disease mutation induces a stronger phenotype than wild-type α-synuclein (reviewed in Fernagut and Chesselet [2004] ). Transgenic α-synuclein induced a loss of motor neurons (shown for mice expressing human A30P mutant α-synuclein in Figures 1C and 1D) ; this neuropathology correlated with the formation of insoluble α-synuclein aggregates (Figures 1E and S2) . Strikingly, mice overexpressing murine α-synuclein did not develop a neurodegenerative phenotype ( Figure 1B ; tested in five independent lines [data not shown]), in spite of the fact that the transgenic expression levels of mouse and human α-synuclein were similar ( Figure 1A) . The lack of a pathogenic effect by wild-type mouse α-synuclein suggests that the neurodegeneration induced by human α-synuclein does not reflect a general physiological function of α-synuclein.
Transgenic ␣-Synuclein Prevents the Lethal Neurodegeneration in CSP␣ KO Mice
To study the relation between the late-onset neurodegeneration caused by transgenic α-synuclein (Figure 1 ) and CSPα chaperone activity (Fernández-Chacón et al., 2004), we crossed transgenic α-synuclein and CSPα KO mice and produced mice that are homozygous for the CSPα deletion and hemizygous for the α-synuclein transgene (Figure 2A ). In these breedings, all comparisons were made between littermate mice to limit potentially confounding background effects. Unexpectedly, we found that transgenic α-synuclein expression abolished the fulminant neurodegeneration observed in CSPα KO mice.
Homozygous CSPα KO mice appear to be comparatively normal at birth but exhibit a relative loss of body weight after postnatal day P20 and begin to perish after 1 month; no CSPα KO mouse survived beyond 4 months of age (Fernández-Chacón et al., 2004; Figure  2 ). Transgenic expression of human or mouse wild-type α-synuclein or of human A53T mutant α-synuclein prevented the weight loss and completely abolished the lethality of CSPα KO mice ( Figures 2D, 2E , and S3). In contrast, transgenic A30P mutant human α-synuclein, in two independent lines, was unable to suppress the CSPα KO phenotype ( Figures 2D, 2E , and S4), even though A30P mutant α-synuclein was expressed at the same level and in the same pattern as wild-type human and mouse α-synuclein ( Figures 1A and S1 ). CSPα KO mice that survive because they express human A53T mutant α-synuclein develop the typical late-onset neurodegenerative phenotype observed in α-synuclein transgenic mice, but the CSPα deficiency did not appear to accelerate the α-synuclein-induced phenotype in these mice (data not shown).
The neurodegeneration caused by the CSPα deficiency leads to gliosis that is visualized as increased expression of the astrocyte protein GFAP. The gliosis was also reversed by transgenic wild-type α-synuclein ( Figures 3A and S5 
Deletion of ␣-and ␤-Synucleins Exacerbates the CSP␣ KO Phenotype
The fact that overexpression of exogenous α-synuclein reverses the lethality of CSPα KO mice suggests that Before postnatal day P20, CSPα KO mice containing endogenous α-and β-synucleins were indistinguishable in weight from control mice ( Figure 2D ). In contrast, already at postnatal day P8 the CSPα KO mice that additionally lack α-and β-synucleins weighed less than their littermates and at P20 were half the size of their CSPα wild-type littermates ( Figure 5A ). Furthermore, triple KO mice lacking CSPα and α-and β-synucleins died precipitously within a few days after weaning (average life span = 23.8 ± 0.7 days; n = 12), whereas CSPα KO mice expressing endogenous synucleins exhibited an extended mortality curve (average life span = 62.3 ± 2.2 days; n = 102; Figure 5B ). Even when triple KO mice lacking CSPα and α-and β-synucleins were not weaned but left with their mothers, these mice did not survive for more than 30 days. Double-KO mice that lacked both CSPα and α-synuclein but contained β-synuclein revealed an intermediate mortality curve ( Figure 5B), suggesting that α-and β-synuclein are redundant in this effect. The acceleration of the CSPα KO lethality by deletion of synucleins was accompanied by an accelerated neurodegeneration, as evidenced by the absence of GFAP staining of gray matter in CSPα KO mice containing endogenous synucleins at P10 but its presence in CSPα KO mice lacking synucleins (Figure S7 ).
␣-Synuclein and CSP␣ Function Independently but Cell Autonomously
Rescue of a lethal mouse mutant by a nonrelated transgene is highly unusual, if not unique. This raises the question whether transgenic α-synuclein acts cell autonomously in collaboration with CSPα or operates indirectly by a hormonal, developmental, or fortuitous action. In addressing this question, we noticed that retinal photoreceptor degeneration in CSPα KO mice is not rescued by the α-synuclein transgenes ( Figure 6A ). We then tested whether transgenic α-synuclein is expressed in photoreceptor cells and found that it was only present in the inner plexiform synaptic layer, but not in photoreceptor synapses (Figures 6B and S8 ). In keeping with this observation, CSPα KO mice rescued by the α-synuclein transgene fail in behavioral tests that require normal eyesight ( Figure S9) .
The photoreceptor data indicate that α-synuclein only rescues neurodegeneration in cells that express the transgene, suggesting that α-synuclein may either function as a cochaperone that cooperates with CSPα (and functionally replaces it in the KO mice) or function downstream of CSPα to prevent the deleterious consequences of the CSPα deficiency. To distinguish among these hypotheses, we first tested whether α-synuclein interacts with the chaperone Hsc70 and the cochaperone SGT similar to CSPα (Tobaben et al., 2001) . However, we found that both in immunoprecipitation ( Figure   S10A ) and in GST-pull-down experiments ( Figure S11) , there was no interaction (even when nonhydrolysable ATP analogs were added), nor was there binding of α-synuclein to CSPα. These results show that α-synuclein does not stably interact with the chaperones that constitute the enzymatically active CSPα-dependent chaperone complex. To test for a more transient interaction, we next explored the possibility that α-synuclein may replace CSPα in stimulating the Hsc70 ATPase activity, even if it does not stably interact with Hsc70. Although CSPα (as reported earlier; Braun et al., 1996; Chamberlain and Burgoyne, 1997) powerfully stimulated Hsc70 ATPase activity, α-synuclein had no effect on the Hsc70 ATPase activity even in the presence of SGT and furthermore did not alter the stimulation of Hsc70 ATPase by CSPα ( Figure S12 ). Finally, we explored the possibility that α-synuclein may be a general chaperone that protects against all types of neurodegeneration by crossing transgenic α-synuclein mice with transgenic mice that express mutant superoxide dismutase (SOD) which cause a spinal cord neurodegeneration similar to that observed in CSPα KO mice (Gurney et al., 1994) . However, we found that transgenic α-synuclein had no beneficial effect on this mutant ( Figure S13 ). Together, these data indicate that α-synuclein has no cochaperone function and rescues the CSPα deficiency phenotype not by functionally re- Transgenic overexpression of wild-type α-synuclein did not reverse the decline in SNAP-25 levels in CSPα KO mice ( Figure 7D and Table S2 ). Even at 13 months of age (9 months after the time at which CSPα KO mice lacking an α-synuclein transgene perish), CSPα KO mice containing a wild-type α-synuclein transgene still exhibit decreased SNAP-25 levels ( Figures 7E and S15) . Transgenic wild-type α-synucleins did, however, reverse the decline in Hsc70 and Hsp70 in the CSPα KO mice (Figure 7D ), although it did not cause a general upregulation of Hsc70, Hsp70, and other chaperones in wild-type mice (Table S2) , consistent with the conclusion that α-synuclein is not a nonspecific activator of chaperones (see above).
The protein quantitations suggest that α-synuclein and CSPα may alter SNARE function but do not act via the same mechanism. This conclusion is supported by the finding that neither CSPα nor α-synuclein coimmunoprecipitated one of the three synaptic SNARE proteins (SNAP-25, synaptobrevin, or syntaxin; Figures S10B and S10C). Although this result does not rule out a weak interaction between α-synuclein, CSPα, and mogenates by solubilization in 1% Triton X-100 and quantified the amount of SNARE proteins and of complexins (which bind only to assembled SNARE complexes and thus report on the presence of SNARE complexes; McMahon et al., 1995) in the immunoprecipitates using 125 I-labeled secondary antibodies and phosphoimager detection. We found a significant decrease in SNARE complexes in CSPα KO mice; this decrease was reversed by transgenic wild-type α-synuclein but not by A30P mutant α-synuclein (Figures 8A-8C) . These results were confirmed with an independent assay in which SNARE complex assembly is measured on SDS gels of nonboiled samples ( Figure S16 ). These data suggest that SNARE complex assembly is abnormal in the CSPα KO mice but can be corrected by expression of wild-type human α-synuclein.
Discussion
In the present study, we show that transgenic expression of α-synuclein unexpectedly prevented the fulminant lethal neurodegeneration caused by deletion of CSPα. CSPα-deficient mice without transgenic α-synuclein die within a few months, but CSPα-deficient mice expressing transgenic α-synuclein survive for >15 months (Figures 2, S3, and S15) . Transgenic α-synuclein reversed the weight loss (Figure 2) , neuropathological phenotype (Figures 3, S5, and S6) , and motor impairment (Figure 4) caused by the CSPα deficiency and acted in a cell-autonomous manner (Figure 6 ). Conversely, deletion of endogenous synucleins accelerated the lethal neurodegeneration in CSPα-deficient mice (Figures 5 and S7) . The CSPα deletion induced selective decreases in the levels of the synaptic SNARE protein SNAP-25 and the chaperones Hsc70 and Hsp70 (Figure 7 ) and impaired SNARE complex assembly (Figures 8 and S16 ). Transgenic wild-type α-synuclein corrected the decreases in Hsc70 and Hsp70 and partly suppressed the defect in SNARE complex assembly but did not reverse the decline in SNAP-25 levels (Figures 7 and 8) . Wild-type murine, wild-type human, and A53T mutant human α-synuclein rescued the CSPα KO phenotype, but A30P mutant human α-synuclein did not (Figures 2-4, 8, S3, and S4) . Together, these data demonstrate that decreasing the overall presynaptic synuclein concentration aggravates the neurodegener- ation caused by CSPα deficiency, whereas increasing the presynaptic synuclein concentration prevents the neurodegeneration. The surprisingly powerful ability of transgenic α-synuclein to abolish the fulminant neurodegeneration of CSPα KO mice prompts the concern that this effect is caused by an artifact, for example a particular transgene insertion site or a genetic background effect. However, three facts argue against this possibility. First, multiple independent lines of transgenic α-synuclein mice suppressed the lethal CSPα deficiency phenotype, demonstrating that transgene integration cannot be responsible. Conversely, two independent lines of A30P mutant α-synuclein were unable to rescue. The fact that a single amino acid substitution abolishes rescue ensures the specificity of the effect (Figures 2 and  S4) . Second, all of our mouse crossings were performed on hybrid backgrounds, avoiding confounding homozygous mutations that can occur in inbred strains.
Lastly and most importantly, deletion of endogenous synucleins accelerated the development of the CSPα KO phenotype, thereby demonstrating that synuclein levels determine the CSPα deficiency phenotype in both directions.
How does the level of presynaptic α-synuclein determine whether or not CSPα deficiency causes neurodegeneration? In CSPα KO mice expressing transgenic α-synuclein, photoreceptor neurons selectively lack transgenic α-synuclein and photoreceptor neuron neurodegeneration is selectively not rescued (Figure 6 ), suggesting that α-synuclein functions cell autonomously and has to be present in CSPα-deficient neurons in order to suppress their degeneration. In preventing neurodegeneration caused by the CSPα deficiency, α-synuclein does not functionally replace CSPα as a cochaperone or act as a general chaperone. This conclusion is based on the fact that α-synuclein does not interact with Hsc70 or SGT (the two proteins that form an enzymati-cally active chaperone with CSPα) and does not alter the ATPase activity of Hsc70 (Figures S11 and S12) . Moreover, transgenic α-synuclein does not ameliorate neurodegeneration caused by overexpression of mutant SOD (Figure S13 ), consistent with a lack of a general chaperone activity. Finally, α-synuclein is unable to reverse the w50% decrease in SNAP-25 levels in the CSPα KO mice, even though it rescues their lethality and neurodegeneration, indicating that α-synuclein functions downstream of CSPα instead of replacing CSPα (Figure 7) .
In solution, α-synuclein exists in a random coil conformation. In the presence of phospholipid membranes (such as in an intracellular environment), α-synuclein folds into amphipathic α helices that coat the phospholipids (Eliezer et al., 2001; Chandra et al., 2003) . We found that α-synuclein only rescues the lethality of CSPα KO mice when α-synuclein is fully capable of binding to phospholipids in an α-helical conformation. This was demonstrated by the fact that a single amino acid substitution, A30P, abolishes the ability of α-synuclein to rescue (Figures 2-4 Figures 2 and 4) . Since CSPα is also peripherally bound to synaptic vesicles, both α-synuclein and CSPα are presynaptic proteins that function when attached to synaptic vesicle phospholipids (although by different mechanisms), indicating that they both may act directly or indirectly on the vesicle membrane.
The CSPα deficiency causes a selective decline in SNAP-25 levels that is present early in development, before significant neurodegeneration is detected (Figure 7B) , and is observed even in cultured neurons (Figure 7C (Figures 8 and S16) , and transgenic wildtype but not A30P mutant α-synuclein rescues, at least in part, this impairment. In the nerve terminal, every round of synaptic vesicle exo-and endocytosis requires the assembly and dissociation of SNARE complexes (reviewed in Jahn [2004] Hardy, 2003) . This observation raises the possibility that sequestration of α-synuclein into Lewy bodies may decrease effective α-synuclein levels in nerve terminals and may contribute to neurodegeneration. Testing this speculative hypothesis will require screening patients with neurodegenerative diseases for polymorphisms in the CSPα or synuclein genes and identifying conditions in which expression of these proteins is altered. Independent of whether this hypothesis is correct, however, our data indicate that α-synuclein is linked to neurodegeneration via two distinct mechanisms: a previously appreciated dominant-negative action of mutant or overexpressed α-synuclein and a physiological neuroprotective action of normally expressed α-synuclein.
Experimental Procedures
Generation, Breeding, and Analysis of Transgenic Mice and KO Mice Transgenic mice that express wild-type or mutant α-synucleins under the control of the Thy-1 promoter (Andra et al., 1996) were produced as described (Missler et al., 2003; 
